Although there is currently is no evidence from prospective studies to support a change in the treatment algorithm, the treatment options for patients with HPV-positive disease are likely to change in the future.
the Surveillance, Epidemiology, and End Results (SEER) programme, the incidence of oropharyngeal cancers increased by 1.3% for tongue base cancers and by 0.6% for cancers of the tonsil for each year between 1973 and 2004 [3] . In contrast, the incidence of oral cavity cancers has declined by 1.9% every year during this period [3] . This has been seen worldwide, particularly in the developed world [4] . This is demonstrated in Fig. 1 , adapted from the data supplement from Chaturvedi et al. [4] .
Head and neck SCC has been associated with tobacco smoking, and the cancer incidence in these anatomical sites has mirrored smoking rates [5] . There has been a decreasing trend in tobacco usage in the developed world and decreasing rates of head and neck cancer in all mucosal sites, except for the oropharynx [6] .
Human papillomavirus (HPV) was first identified as a possible etiological agent in oral SCC in 1983 [7] . The oncogenic potential of HPVs in squamous epithelium has been understood for many years following work in uterine cervix and ano-genital squamous cell cancers [8] . A causal link between HPV and oropharyngeal cancer was shown in a study by Gillison et al. [9] , which added further support to the epidemiological and molecular evidence for HPV as the etiological factor in the increasing incidence of oropharyngeal SCC [10] . The International Agency for Research on Cancer in 2007 added HPV type 16 as a cause of oropharyngeal carcinoma [11] .
Importantly, oropharyngeal cancers due to HPV have a different epidemiology, prognosis, response to treatment, and outcome. The implications of this for therapy are under investigation, and this subset of patients may be able to undergo treatments with less toxicity.
It may also allow for targeted therapies related to the different underlying molecular genotype. This review presents a summary of HPV related oropharyngeal carcinoma and highlights potential therapeutic options that may become available for these patients. This article is based on previously conducted studies and does not involve any new studies Fig. 1 The net drift percentage (net drift represents the net sum of the linear trend in period and cohort effects from age-cohort-period models) in oropharyngeal and oral cavity cancers among men stratified by age (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) ) for selected countries [4] . Black square oropharynx, white square oral cavity. Adapted with permission from Chaturvedi et al. [4] of human or animal subjects performed by any of the authors.
HPV AND OROPHARYNGEAL SCC
HPVs comprise 150 small non-enveloped DNA viruses that have double-stranded and circular genomes [12] . They share a similar segment in their genome called the L1 gene that encodes for the major capsid protein. They can be divided into mucosal and cutaneous types. They are further classified into high-risk and low-risk viruses depending on their ability to induce cancer. HPV 16 is a high-risk virus that has been associated with up to 90% of HPV-related head and neck cancer in mucosal surfaces. The other HPV genotypes have a prevalence of less than 5% in oropharyngeal tumors [13, 14] .
The life cycle of HPV viruses is closely related to the differentiation of the squamous cell it infects [12] . Initially the virus targets and infects the basal squamous cells at the deep aspect of the skin or mucosa. It will gain access after trauma or erosion of the superficial layers. A low virus genome copy count of approximately ten is maintained in these cells. The virus is able to take over the cell's replication machinery [15] and maintain the cell's ability to synthesize DNA, which is usually lost as the cell differentiates. As the cell starts differentiation, the productive phase of virus replication is started, where up to 1000 viral genome copies are produced along with expression of the viral L proteins [12] . Mature virus progeny particles are then released into the uppermost layers of the epithelium.
The tonsil epithelium has a specialized morphology. The tonsil has multiple crypts, and these have specialized stratified squamous non-keratinizing epithelium and patches of reticulated sponge-like epithelium [16] . These perform a function in antigen recognition as part of the immune system [16] . HPV is thought to access the oropharyngeal mucosa via the tonsillar crypts [17] , through the specialized porous membrane. The mechanism of viral entry into the cell is not fully understood, but is thought to involve a6b4 integrins [18] and cell surface heparin sulfate proteoglycans (HSPGs) [19] . Once a cell is infected, the natural history of infection is not well understood in the oropharynx. The proportion of infections that enter an acute, chronic, or latent phase or are cleared by the host's immune system is not clear [12] . However, it is thought that most oral HPV infections are cleared within a year [20] .
A prevalence study in the US as part of the National Health and Nutrition Examination Survey (NHANES) in 2009-2010 [21] showed the prevalence of oral HPV infection among men and women aged 14-69 years was 6.9% and of HPV type 16 was 1.0%. A more recent systematic review showed a prevalence of 4.5% in 4070 subjects for any HPV type [22] and prevalence of 1.3% for HPV 16 . The implication of HPV 16 infection was shown in a case control study in which an odds ratio of 14.6 [95% confidence interval (CI), 6.3-36.6] was seen in patients with newly diagnosed oropharyngeal cancer compared to cancer-free controls [23] .
Following infection with HPV there is a latency period and a stepwise progression towards genomic instability [12] have been correlated with outcome in these patients [29] . The E5 protein is thought to increase epidermal growth factor receptor (EGFR) recycling to the cell surface, and this has been seen in cervical cancers [30] , but its role in head and neck cancer is yet to be defined.
There are a number of different ways to detect HPV infection, but there is no worldwide consensus on which is best. Each detection method has its own associated strengths and weaknesses, and methods vary throughout the world [31] . The main aim is to identify transcriptionally active high-risk HPV.
Methods vary from routine histology, polymerase chain reaction (PCR) for viral DNA or RNA, in situ hybridization to immunohistochemistry. The identification of high-risk HPV DNA and the over-expression of p16 (a surrogate marker for infection) are important in diagnosing HPV-related tumors [32] .
COMPARISON OF HPV-POSITIVE AND HPV-NEGATIVE TUMORS OF THE OROPHARYNX

Clinicopathological Characteristics
Following the application of highly sensitive HPV detection methods and a rigorous definition of active HPV transcription, the vast majority of HPV-positive tumors have been shown to be located in the oropharynx, mostly in the tongue base and tonsil [31] , and rarely in other head and neck sites. The correlation of HPV-related tumors and high-risk sub-sites in Waldeyer's ring is an important and significant difference between HPV-positive and HPV-negative tumors. Two large meta-analyses have shown HPV infection is strongly associated with tonsillar and base of tongue sites [33, 34] . However, it is important to understand that the testing method can be a source of heterogeneity when comparing studies [33] . In contrast, HPV-negative tumors do not have a predilection to a particular sub-site in the head and neck [35] and field cancerization is more common.
In modern series, approximately 50% of oropharyngeal cancers have detectable HPV DNA on testing [36] , with some reporting higher rates, depending on the studied population. In a United Kingdom (UK) series, HPV-related cancers were identified in 70% of the oropharyngeal tumors [37] . The high-risk HPV 16 subtype is found in 90% of these cancers with other high-risk subtypes 31, 33, and 18 identified in the other cases [36] . In comparison, transcriptionally active high-risk HPV DNA is rarely seen in other sites in the head and neck and in oropharyngeal sub-sites such as the soft palate and posterior pharynx [37] . Overall population trends in the US SEER data have shown the incidence of oropharyngeal squamous cell cancer is higher in men compared to women and more common in black people compared to other races [3] .
However, when HPV-related cancers are examined these trends are different.
HPV-related oropharyngeal cancers have been seen specifically in white men and an increasing incidence trend for men compared to women in other races [3] . There is also an association between educated middle class patients and HPV-positive cancers [38] .
Tobacco use is a well-known risk factor for head and neck cancer and has a synergistic effect with alcohol [40] . They have been identified as major risk factors for head and neck and oropharynx carcinoma in a large multicenter consortium study including 25,500 patients [41] . However, studies investigating patients with HPV-positive tumors report patients are more likely to be non-smokers [42] , and overall tobacco use is lower compared to patients with HPV-negative tumors. Cohorts of patients with HPV-positive tumors consist of about 30% nonsmokers compared with less than 5% in the HPV-negative groups [43] . This relationship has been reported in many studies [44] . However, smoking in patients with HPV 16 infection has recently been examined in the NHANES survey in the US [45] . In the 6887 participants, bivariable analysis reported tobacco use was associated with HPV 16 infection. Therefore, there is more to understand about the interaction of tobacco and HPV infection. The effect of tobacco use on prognosis and outcomes is discussed below.
Infection of the uterine cervical and ano-genital region with high-risk HPV is transmitted through sexual contact [8] . Therefore, the mode of infection of high-risk HPV subtypes in the oropharynx has been investigated with regard to sexual behaviors. There are also differences in the histopathology between HPV-positive tumors and HPV-negative tumors. HPV-positive tumors are more likely to be non-keratinizing and undifferentiated. In a study of 253 tumors a basaloid or poorly differentiated SCC subtype was associated with viral genome in the tumors cells [9] . However, the more aggressive histological features of HPV-related carcinomas are not related to prognosis or outcomes following treatment.
Comparison of Outcomes
Survival and therapeutic response was prospectively studied as part of the Eastern Cooperative Oncology Group (ECOG) 2399 protocol in which patients with stages III and IV head and neck cancers were treated with induction chemotherapy [49] . Following assessment of response, responders received chemo-radiation and non-responders received either surgical resection or chemo-radiation. Patients with HPV-positive disease had a higher response rate to induction chemotherapy and chemo-radiotherapy. They also had a better overall survival at two years of 95% (95% CI 87-100%) compared with 62% (95% CI 49-74%) in HPV-negative tumors [49] .
There has been a large number of [29, 33, 49, 52] . Figure 2 shows the Kaplan-Meier curve for overall survival stratified by HPV status from this study [49] . The use of tobacco was also identified as an independent factor in the prognosis of patients with HPV-positive and HPV-negative tumors.
Smoking has also been correlated with a worse outcome in other studies [49] . However, each additional pack-year was seen to decrease survival and following the incorporation of the tumor, node, metastasis (TNM) stage with HPV status, and smoking history stratification This trend has been shown in meta-analysis of studies worldwide. In a meta-analysis reporting on 5681 patients, the prevalence of HPV tumors was 22%, and this was associated with an improved survival with a hazard ratio of 0.42 (95% CI 0.27-0.57) [29] .
Factors that Predict Outcome
The 
Molecular (Genomic) Comparison
The reason why HPV-positive and HPV-negative cancers behave differently is due to the difference in the mutational landscape of these cancers. In two studies performing whole sequencing of exons (all known protein-encoding genes) in head and neck cancers published in 2011 [57, 58] , dominant roles were seen for tumor-suppressor pathways including p53, Rb/INK4/ARF, and Notch in disease pathogenesis. However, only a small number of oncogene-activating mutations were identified. The vast majority of the tumors in these studies were HPV negative (28/32 and 80/92). These studies found fewer genes were mutated per tumor in the HPV-associated tumors as compared with those tumors not related to HPV [57] .
TP53 mutations were not identified in any of the HPV-positive tumors in one study [57] , but were seen in 78% of HPV-negative tumors. There was also an increased number in mutations in tobacco-related cancers compared to non-tobacco-related cancers. The Cancer Genome Atlas Network (TCGA) recently published findings on the assessment of 279 patients with head and neck cancer, assessing for somatic genomic alterations [59] .
This study has shown a difference between [35] . It has also been linked with nuclear factor-jB, which provides an important survival signal to cells [63] . These have been linked with metastasis and invasion [64] . head and neck cancers [35] . These appear to feature in over 50% of HPV-positive tumors and in 30% of HPV-negative tumors [59] .
TREATMENT APPROACHES IN HPV-POSITIVE DISEASE
There are major differences in the risk factors, identified as related to head and neck cancers.
These clinical trials are summarized into surgical trials, trials using modification of standard radiotherapy/chemotherapy techniques, and new agents and immune therapies.
Prevention
Prevention of a virally related malignancy can be divided into primary and secondary prevention [68] . Figure 6 shows the protocol for the study. Another trial that will de-intensify treatment based on response to induction chemotherapy is the OPTIMA trial. Nab-paclitaxel and carboplatin will be followed by response-based therapy of chemo-radiation of high or low dose Another trial considered a reduced radiation dose to the nodal basins but it is currently suspended (ClinicalTrials.gov identifier, NCT01891695). A different group had planned to treat patients with low-risk HPV-related oropharyngeal SCC and a N0 neck with a de-intensification of radiation and chemotherapy (ClinicalTrials.gov identifier, NCT02281955), but this study has also suspended recruitment.
A meta-analysis of RCTs that performed post hoc stratification for HPV analyzed five trials.
They suggested HPV-positive groups were a heterogeneous population with non-smokers demonstrating improved survival compared to smokers. They concluded that de-intensification in HPV-positive smokers had to be carefully assessed for safety [86] . 
New Agents and Immune Therapy
Immune Therapy and Vaccines
Immune therapy and vaccines offer a different modality for the treatment of oropharyngeal SCC that has not been available before. This is because foreign viral antigens that are present in cancers cells could be amenable to targeted therapy. This is supported by the local presence of HPV16-specific T cell immunity found in HPV-16-induced SCC [89] .
Genetically Modified T Cell Response T cells can be used as an autologous transfusion in a process termed adoptive immunotherapy. In the past, melanoma and viral-associated malignancies have been responsive to this type of therapy [90] and it is being investigated for use in head and neck cancers. DNA vaccines DNA vaccines are also being evaluated in the treatment of head and neck cancers. The delivery method of DNA vaccines is important and a number of studies are evaluating electroporation delivery of vaccine [91] . The efficacy of DNA vaccines in a murine model has been shown [92] 
